Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment [Yahoo! Finance]
NLS Pharmaceutics Ltd. - Ordinary Shares (NLSP)
Company Research
Source: Yahoo! Finance
ZURICH and NESS ZIONA, Israel Feb. 25, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd . (TASE: KDST) ("Kadimastem"), a clinical-stage company specializing in "off-the-shelf" allogeneic cell therapy products for neurodegenerative diseases and diabetes, in collaboration with iTolerance Inc. ("iTolerance"), a U.S. based regenerative medicine company, announced today the result from the Type B pre-IND meeting held by Kadimastem and iTolerance with a committee of the U.S Food and Drug Administration ("FDA") on February 24, 2025 , regarding the development of iTOL-102, a potential cure for diabetes that would not require life-long chronic immune system suppression. iTOL-102 is an investigational biologic for the treatment and potential cure of Type 1 Diabetes consisting of Kadimastem's allogenic human stem cell-derived pancreatic islets (IsletRx cells) combined with iTolerance's immunomodulator (iTOL-100). Ronen Twito, Kadimastem's Executive Chairm
Show less
Read more
Impact Snapshot
Event Time:
NLSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NLSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NLSP alerts
High impacting NLS Pharmaceutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NLSP
News
- NLS Pharmaceutics (NASDAQ:NLSP) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=NLSP&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger [Yahoo! Finance]Yahoo! Finance
- NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerPR Newswire
- NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsPR Newswire
- NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following MergerPR Newswire
NLSP
Sec Filings
- 11/13/25 - Form SCHEDULE
- 11/3/25 - Form 6-K
- 10/30/25 - Form 25-NSE/A
- NLSP's page on the SEC website